Here's Why Array BioPharma Jumped 31% in January

Shares of Array BioPharma (NASDAQ: ARRY), an oncology-focused biopharmaceutical company, rose 31% in January, according to data from S&P Global Market Intelligence. Last month, Eli Lilly (NYSE: LLY) agreed to pay $8 billion for a few drugs that Array still owns a piece of. Also, a combination therapy Array already markets took a big step toward an important label expansion.